Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20640604 | 0.77 | GAA (0.44) | GAAALDH1A1NPC1HTTRET | |
| SCHEMBL30134356 | 0.76 | MAPT (0.39) | GAAALDH1A1LMNA | |
| SCHEMBL25753216 | 0.74 | GAA (0.36) | GAAALDH1A1NPC1LMNAPOLB | |
| SCHEMBL21152701 | 0.73 | GAA (0.51) | GAAALDH1A1RETLMNAPOLB | |
| SCHEMBL22235822 | 0.72 | GAA (0.36) | GAAALDH1A1RETLMNAPOLB | |
| SCHEMBL22207247 | 0.72 | GAA (0.36) | GAAALDH1A1RETLMNAPOLB | |
| SCHEMBL26695909 | 0.71 | ALDH1A1 (0.42) | GAAALDH1A1LMNAPOLBPKM | |
| SCHEMBL25405989 | 0.71 | CYP4F2 (0.41) | GAAALDH1A1HTTRETLMNA | |
| SCHEMBL31106066 | 0.71 | GAA (0.39) | GAAALDH1A1RETTDP1KMT2A | |
| SCHEMBL17675453 | 0.71 | GAA (0.49) | GAAALDH1A1RETLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620949-B | Synthesis method of antitumor compound and intermediate thereof | 药捷安康(南京)科技股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | SQLE, HCCS, DHPS | GAA 339/4885ALDH1A1 1276/4885NPC1 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.